United Therapeutics (NASDAQ:UTHR) Director Sells $978,840.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) Director Tommy Thompson sold 2,000 shares of the stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $489.42, for a total transaction of $978,840.00. Following the sale, the director directly owned 8,480 shares in the company, valued at $4,150,281.60. This represents a 19.08% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.

United Therapeutics Price Performance

Shares of UTHR stock traded down $5.15 during trading on Thursday, reaching $485.06. The company’s stock had a trading volume of 420,755 shares, compared to its average volume of 381,036. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $537.19. The stock’s 50-day moving average price is $483.67 and its 200 day moving average price is $450.90. The company has a market capitalization of $21.26 billion, a price-to-earnings ratio of 17.39, a P/E/G ratio of 1.79 and a beta of 0.84.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.78 by $0.92. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The company had revenue of $790.20 million for the quarter, compared to analyst estimates of $814.80 million. During the same period in the prior year, the business earned $6.19 EPS. The firm’s quarterly revenue was up 7.4% on a year-over-year basis. On average, sell-side analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Wells Fargo & Company upped their target price on United Therapeutics from $423.00 to $466.00 and gave the company an “equal weight” rating in a research report on Thursday, February 26th. UBS Group upped their price target on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research note on Thursday. TD Cowen lifted their target price on shares of United Therapeutics from $525.00 to $575.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Jefferies Financial Group restated a “buy” rating on shares of United Therapeutics in a research report on Monday. Finally, Oppenheimer boosted their target price on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Nine analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $539.00.

Institutional Trading of United Therapeutics

Large investors have recently modified their holdings of the business. Rehmann Capital Advisory Group raised its position in shares of United Therapeutics by 9.8% during the 4th quarter. Rehmann Capital Advisory Group now owns 3,619 shares of the biotechnology company’s stock worth $1,767,000 after purchasing an additional 324 shares during the last quarter. Tobam increased its position in United Therapeutics by 28.9% during the fourth quarter. Tobam now owns 9,857 shares of the biotechnology company’s stock worth $4,803,000 after buying an additional 2,211 shares in the last quarter. Wick Capital Partners LLC purchased a new position in United Therapeutics during the fourth quarter worth $297,000. Mishpacha Holdings Corp acquired a new position in shares of United Therapeutics in the fourth quarter worth $487,000. Finally, Seven Fleet Capital Management LP purchased a new stake in shares of United Therapeutics in the fourth quarter valued at $633,000. 94.08% of the stock is currently owned by institutional investors and hedge funds.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.